Two drug molecules enhance remyelination in multiple sclerosis models

Two Drug Molecules Show Promise for Repairing Nerve Damage in Multiple Sclerosis

In a breakthrough for MS research, a University of Helsinki doctoral thesis has identified two drug molecules that successfully promote remyelination in animal and cell models, offering a potential path toward treatments that repair—not just manage—neural damage.

A New Frontier in MS Treatment

Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks the myelin sheath, the protective layer surrounding nerve cells. This damage disrupts nerve signaling, leading to a range of debilitating neurological symptoms. While current treatments can suppress immune activity, they do not repair the damage already done.

Now, research from the University of Helsinki offers a new approach. In his doctoral thesis, Tapani Koppinen has identified two drug molecules that promote remyelination—the process of rebuilding damaged myelin—in cellular and animal models of MS.

Two Approaches, One Goal: Repair

The research tackles the problem from two distinct angles.

• This strategy targets a stress mechanism in brain cells that naturally inhibits tissue repair.
• By blocking this mechanism with a specific drug molecule, researchers were able to significantly enhance remyelination in brain tissue damaged by MS-like conditions.
• The findings from this study were published in February.

• This approach focuses on scar tissue, which forms a physical barrier preventing neural regeneration.
• By altering the composition of that scar tissue with a second drug molecule, the research team successfully promoted neuronal recovery.

In both disease models, the drugs led to substantial remyelination and a marked reduction in neuroinflammation.

The Road to Human Testing

While the results are promising, significant hurdles remain before these molecules can reach patients.

• Complex Human Biology: The molecules must now be tested in humans, where tissue conditions are far more complex than in laboratory models.
• The Blood-Brain Barrier: This protective barrier can prevent drugs from reaching the central nervous system. However, both molecules were shown to successfully enter the central nervous system in laboratory animals.

The ultimate goal is to advance these molecules into clinical trials, with the hope of developing the first-ever remyelination-enhancing drugs for MS.

Thesis Defense Details

Tapani Koppinen will defend his doctoral thesis on 8 May 2026 at 13:00 at the Faculty of Pharmacy, University of Helsinki.

• Opponent: Professor Robin Franklin, University of Cambridge.
• Thesis Supervisor & Custos: Associate Professor Merja Voutilainen.
• The thesis is available electronically.